Ms. Valerie Celeste Jones, O.T.R./L Occupational Therapist - Physical Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 111 W Calaveras St, Altadena, CA 91001 Phone: 626-398-8971 Fax: 626-398-8971 |
Kiley Krekorian Hanish, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1671 Veranada Ave, Altadena, CA 91001 Phone: 310-403-3856 |
Jordan Warlick Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2253 Mar Vista Ave, Altadena, CA 91001 Phone: 626-201-1949 |
Dr. Ariel Ann Griffith, OTR Occupational Therapist Medicare: Medicare Enrolled Practice Location: 2212 El Molino Ave, Altadena, CA 91001 Phone: 877-369-6650 |
Mr. Sergio Espanto, OTR/L, CHT Occupational Therapist - Ergonomics Medicare: Medicare Enrolled Practice Location: 657 E Mendocino St, Altadena, CA 91001 Phone: 323-828-7718 Fax: 626-798-4743 |
News Archive
Asthma patients, with a specific genetic profile, exhibit more intense symptoms following exposure to traffic pollution, according to researchers at the National Institutes of Health and collaborators. The study appeared online in Scientific Reports.
Northeastern professor of chemical engineering Shashi Murthy has received a four-year, $1.4 million award from the National Institutes of Health to develop a novel instrument that would automate an important process used in creating effective vaccines.
Focusing on the disparities in the quality of health care across demographic groups, the Fourth Annual National Conference on Health Disparities brought together White House officials and national and local healthcare executives to address a series of key questions about non-medical determinants of health quality and to recommend strategies to bring more equitable healthcare access to the underserved. The determinants discussed at the four-day-long conference, which began November 10, 2010 and concluded Saturday, November 13, 2010, included education levels, health literacy, poverty, public safety, community design, access to care, environmental quality and personal, government and corporate responsibility.
Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.
› Verified 3 days ago